Simphotek partners with Penn in fighting Mesothelioma
EIN Presswire, Apr. 2021 -- Simphotek, Inc., an early-stage biotechnology company advancing its computational platform Dosie™ to assist cancer treatment with photosensitizing drugs, today announced that its computational software tool Dosie™ will be used in a four-year NIH Academic-Industrial Partnership Grant from the National Institute of Biomedical Imaging and Bioengineering (R01EB028778). The grant, titled “In situ PEDSy and light delivery platform for Intracavitory Photodynamic Therapy”, was awarded to a consortium of the Perlman School of Medicine at the University of Pennsylvania with Simphotek, Inc. It involves research into the diagnosis and treatment of mesothelioma with photodynamic therapy (PDT). A major purpose of this research is to develop, evaluate, and clinically test an integrated light delivery and dosimetry platform for the quantitative measurement of PDT. The research includes two components:
University of Pennsylvania’s hardware for in situ PDT dosimetry measurement and light source tracking;
Simphotek’s computational software tool Dosie™ for monitoring light distribution throughout the pleural cavity during photodynamic therapy of mesothelioma.
Dosie™ utilizes real-time Monte Carlo simulation of light distribution coupled with distribution and photokinetics simulation of a photosensitizing drug. The hypothesis is that quantitative modeling of PDT dose by Dosie™ will allow for more effective PDT treatment delivery than current methods which employ only light dose measurements without incorporating a component of photosensitizing drug photokinetics.
